Skip to content

To observe the effect of esketamine on postoperative depression in patients undergoing radical resection of cervical cancer based on micro RNA regulation

Anesthesiology?pathergasiology

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065198
Enrollment
Unknown
Registered
2022-10-31
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

SK1 group:esketamine(0.25 mg/kg)was injected intravenously at 30 minutes after the surgery started
SK2 group:esketamine(0.5 mg/kg)was injected intravenously at 30 minutes after the surgery started
S1 group:An equal volume of saline was injected intravenously at 30 minutes after the surgery started

Sponsors

Ma 'anshan People's Hospital, Anhui Province, China
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: women aged 30-60 years; In accordance with the American Society of Anesthesiologists classification ASA ?-?; Body mass index 27; The patient was approved and volunteered to participate in the study, and the patient signed the informed consent to participate in the study;

Exclusion criteria

Exclusion criteria: Patients with Serious cardiovascular and cerebrovascular diseases and severe hypertension; Preoperative psychiatric abnormalities (including preoperative Zung Self-rating Depression Scale (SDS) score =50), preoperative self-rating anxiety scale (SAS) score =50, Having visual or sensory impairment; Speech impairment or severe hearing impairment; Increased intracranial pressure and intraocular pressure; Long-term or recent oral sedatives, analgesics, non-steroidal drugs, glucocorticoids, psychotropic drugs, or alcoholics, drug addicts; And allergy to any of the drug components in the study.

Design outcomes

Primary

MeasureTime frame
micro RNA-132;micro RNA-124;BDNF;Hamilton Depression Scale score;

Secondary

MeasureTime frame
5-HT;IL-6;visual analogue scale;Ramsay sedation score;

Countries

China

Contacts

Public ContactJing Jun
ekinglang1983@163.com13965378174

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026